Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the efficacy of nintedanib has been shown in idiopathic pulmonary fibrosis, its efficacy across a broad range of fibrosing lung diseases is unknown.

Related collections

Author and article information

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: Massachusetts Medical Society

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date Created: September 29 2019

Publication date (Electronic): September 29 2019

Affiliations

[1 ]From the Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor (K.R.F.); the National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust (A.U.W.), the National Heart and Lung Institute, Imperial College (A.U.W., A.D., S.L.F.W.), and the Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust (A.D.) — all in London; the National Reference Center for Rare Pulmonary Diseases, Louis Pradel...

Article

DOI: 10.1056/NEJMoa1908681

PubMed ID: 31566307

SO-VID: 4b91ab5c-3299-4a89-be59-7edd2beac04e

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 656

See all cited by

- Version 1